Peregrine Pharmaceuticals reported $4.46M in Selling and Administration Expenses for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Acceleron Pharma XLRN:US $ 45.11M 9.64M
Adamas Pharmaceuticals ADMS:US 29.73M 579K
Agenus AGEN:US $ 21.38M 4.73M
Amgen AMGN:US $ 1.31B 79M
AstraZeneca AZN:LN 2.99B 412M
Biocryst Pharmaceuticals BCRX:US $ 34.99M 8.67M
Bristol Myers Squibb BMY:US $ 1.79B 95M
Celldex Therapeutics CLDX:US $ 5.82M 1.52M
Chemocentryx CCXI:US $ 19.6M 100K
Dicerna Pharmaceuticals DRNA:US $ 21.99M 3.47M
Eli Lilly And LLY:US $ 1.58B 107.8M
Flexion Therapeutics FLXN:US $ 26.99M 423K
GlaxoSmithKline GSK:LN 2.5B 6M
Immunogen IMGN:US $ 10.3M 569K
Intrexon XON:US $ 18.66M 1.34M
Karyopharm Therapeutics KPTI:US $ 35.1M 1.43M
Kindred Biosciences KIN:US 5.87M 1.18M
Macrogenics MGNX:US $ 17.16M 1.93M
Mannkind MNKD:US $ 17.22M 2.84M
Merk MRK:US $ 2.27B 9M
Minerva Neurosciences NERV:US $ 3M 437.6K
Newlink Genetics NLNK:US 3.38M 1.18M
Novartis NOVN:VX 3.6B 109M
Novavax NVAX:US $ 77.79M 4.63M
Repligen RGEN:US $ 49.97M 7.13M
Xencor XNCR:US $ 10.37M 1.51M